bims-tyki2d Biomed News
on Thymidine kinase 2 deficiency
Issue of 2026–11–08
three papers selected by
Zoya Panahloo, UCB



  1. J Inherit Metab Dis. 2026 Nov;pii: e70263. [Epub ahead of print]49(6):
      Thymidine kinase 2 deficiency (TK2d) is an ultra-rare autosomal recessive mitochondrial DNA (mtDNA) maintenance disorder caused by pathogenic variants in the nuclear TK2 gene. Loss of TK2 activity disrupts intramitochondrial deoxynucleotide pools, impairing mtDNA replication and resulting in a spectrum of quantitative (mtDNA depletion) and qualitative (multiple deletions) alterations whose severity is a key determinant of prognosis. Clinically, TK2d presents as a continuous phenotypic spectrum, from rapidly progressive infantile disease to adult-onset forms, predominantly manifesting as progressive myopathy with early bulbar and respiratory involvement, the principal drivers of morbidity and mortality, with overall severity inversely correlated with age at onset. Central nervous system involvement may occur in severe early-onset cases, whilst extramuscular manifestations are otherwise limited, with sensorineural hearing loss and subclinical axonal sensory neuropathy described across the spectrum. Circulating biomarkers, particularly GDF-15, support diagnosis, correlate with disease severity and show dynamic changes with treatment; serum creatinine, muscle MRI fat fraction and forced vital capacity further contribute to prognostic stratification. Oral supplementation with doxecitine and doxribtimine, recently approved by the FDA (2025) and EMA (2026) for patients with symptom onset ≤ 12 years, represents the first disease-modifying therapy for TK2d, demonstrating marked survival benefit, stabilisation of disease progression and partial recovery of motor function. Evidence in adult patients remains limited and largely retrospective, underscoring the need for dedicated prospective studies with outcome measures sensitive to slowly progressive phenotypes.
    Keywords:  GDF‐15; doxecitine and doxribtimine; mitochondrial DNA depletion syndrome; mitochondrial myopathy; thymidine kinase 2 deficiency (TK2d)
    DOI:  https://doi.org/10.1002/jimd.70263
  2. Genome Med. 2026 Aug 10. pii: 173. [Epub ahead of print]18(1):
      Despite advances in sequencing technologies and variant interpretation frameworks, many variants identified in genetic testing, particularly missense variants, remain classified as variants of uncertain significance (VUS), posing ongoing challenges in diagnosis and clinical management. This review explores the ongoing challenges of VUS interpretation in clinical genomics and its impact on patients, clinicians, and healthcare systems. We summarize established strategies that support VUS resolution, including large population reference databases, data-sharing initiatives, computational prediction tools, consensus-based guidelines, deep phenotyping, and functional validation assays. Building on these foundations, we highlight emerging approaches that leverage multi-omics analyses, high-throughput experimental platforms (e.g., saturation genome editing and cell-based morphological assays), and artificial intelligence-driven tools to improve scalability and interpretive accuracy. Together, these complementary approaches aim to reduce uncertainty, increase diagnostic yield, and enhance the clinical utility of genomic testing in both research and precision medicine.
    Keywords:  ClinGen; ClinVar; Clinical genomics; Variant classification; Variant interpretation; Variant reclassification; Variants of uncertain significance
    DOI:  https://doi.org/10.1186/s13073-026-01740-9
  3. Genet Med Open. 2026 ;4 104494
      Genomic testing is being recognized as an integral part of the management of individuals with epilepsy. However, despite the increasing utility of genomic testing in epilepsy, a substantial proportion of patients who are suspected to have a monogenic cause do not receive a molecular diagnosis. Reanalyzing existing genomic data increases the molecular diagnostic yield over time. As our understanding of the molecular components of epilepsy is changing faster than that of many other conditions, the re-analysis of existing genomic data from patients with epilepsy holds considerable potential for improving diagnostic outcomes. Given the complexity involved in the re-analysis of existing genomic data, neurologists may be unsure how to best incorporate this into their clinical practice following an initial uninformative genomic result. Here, we describe recommendations specifically designed to guide the re-analysis of existing genomic data for individuals with epilepsy with an unknown etiology. We synthesize current evidence and apply these findings to the specifics of genetic epilepsy to determine the best approaches to integrate re-analysis into clinical practice in a sustainable manner that maximizes benefits to patients.
    Keywords:  Clinical recommendations; Epilepsy; Genetic testing; Re-analysis intervals; Re-analysis recommendations
    DOI:  https://doi.org/10.1016/j.gimo.2026.104494